Cellex Symposium 2025 Brings Together International Experts to Discuss the Evolving Field of Cell and Gene Therapy
COLOGNE, Germany, Nov. 10, 2025 /PRNewswire/ -- Under the subject "The Evolving Field of Cell and Gene Therapy", Cellex Cell...
Cancer
Medical Care Technologies Inc. (OTC PINK:MDCE) Marches Forward with Breakthrough Patent-Pending AI Healthcare Solutions using Smart Devices
A very unique multi-vertical health AI engine capable of early detection for mental health, wound infection, skin cancer, and disease...
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with...
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with...
CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical...
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it...
Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting SEATTLE, WASHINGTON /...
AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer
OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a...
Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline
Initial Investment of $1 Million Received from Hexstone Capital LLC Upon ClosingMELBOURNE, Australia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Propanc...
Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials
The Company’s operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational...
Vittoria Biotherapeutics Announces Presentation of First-in-Human Interim Phase1 Data for VIPER-101 at ASH2025
PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company pioneering innovative cell therapies, today announced it will...
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
100% of genes strongly recommended by national oncology guidelines are included in the MyRisk TestSALT LAKE CITY, Nov. 10, 2025...
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025
Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells...
Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
Data presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the...
BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
SUNNYVALE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. , a global leader in cellular and cell-derived therapeutics for the...
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement...
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation...
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following...
Onco-Innovations’ Inka Health Publishes Framework on Transportability of Real-World Evidence and Use in Health Technology Assessment
VANCOUVER, BC / ACCESS Newswire / November 7, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")...
Oracle and Ci4CC Partner to Accelerate Oncology Innovation
Strategic collaboration to leverage Ci4CC's national network and Oracle's technology to help advance AI in oncology, EHR interoperability, next-gen clinical...